vårdprogram för bakteriella CNS-infektioner - Infektion.net

25. Paris MM, et al. Effect of dexamethasone on therapy of experimental penicillin- and
cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother. 38: 1320, 1994.
26. Steenbergen JN, et al. Daptomycin: a lipopeptide antibiotic for the treatment of serious Grampositive
infections.J Antimicrob Chemother. 55(3):283-8, 2005.
27. Rybak MJ. The efficacy and safety of daptomycin: first in a new class of antibiotics for Grampositive
bacteria.Clin Microbiol Infect. 12(Suppl 1):24-32, 2006.
28. Cottagnoud P, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillinand
quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother.
48(10):3928-33, 2004.
29. Grandgirard D, et al. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin
in experimental pneumococcal meningitis. Antimicrob Agents Chemother. 51(6):2173-8, 2007.
30. Ramírez P, et al. Linezolid as rescue therapy for pneumococcal meningitis. Intensive Care Med.
33(5):924-5, 2007.
31. Faella F, et al. Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis:
a case series including penicillin-resistant strains. Clin Microbiol Infect. 12(4):391-4, 2006.
32. Uriz S, et al. Neisseria meningitidis with reduced sensitivity to penicillin: Observations
in 10 children. Scand J Infect Dis. 23: 171, 1991.
33. Cebells CL, et al. Clinical data in children with meningococcal meningitis in a Spanish hospital.
Acta Paediatr. 86: 26-9, 1997.
34. Schultz TR, et al. An invasive isolate of Neisseria meningitidis showing decreased susceptibility
to quinolones. Antimicrob Agents Chemother. 44:1166, 2000.
35. Scheld WM, et al. Response to therapy in an experimental model of meningitis due to Listeria
monocytogenes. J Infect Dis. 140: 287, 1979.
36. Merle-Melet M, et al. Is amoxicillin-cotrimoxazole the most appropriate antibiotic regimen for
listeria meningoencephalitis Review of 22 cases and the litterature. Journal of Infection. 33: 79, 1996.
37. Cherubin CE, et al. Treatment of gram-negative bacillay meningitis:role of new cephalosporin
antibiotics. Rev Infect Dis. 4:453S–4564S, 1982.
38. Kaplan SL, et al. Cefotaxime and aminoglycoside treatment of meningitis caused by gram-negative
enteric organisms. Pediatr Infect Dis J. 9: 810, 1990.
39. Fong IW, et al. Review of Pseudomonas meningitis with special emphasis on treatment with
ceftazidime. Rev Infect Dis. 7:604–612, 1985.
40. Rodriguez WJ, et al. Treatment of Pseudomonas meningitis with ceftazidime with or without
concurrent therapy. Pediatr Infect Dis J. 9:83–7, 1990.
41. Jensen AG, et al. Staphylococcus aureus meningitis. A review of 104 nationwide, consecutive
cases. Arch Intern Med. 153:1902–1908, 1993.
42. Ostergaard C, et al. Evaluation of fusidic acid in therapy of experimental Staphylococcus aureus
meningitis. J Antimicrob Chemother. 51: 1301–1305, 2003.
43. Norgaard M, et al. Staphlococcus aureus meningitis: experience with cefuroxime treatment during
a 16 year period in a Danish region. Scand J Infect Dis. 35: 311–314, 2003.
44. Ntziora F, et al. Linezolid for the treatment of patients with central nervous system infection.
Ann Pharmacother. 41(2): 296-308, 2007.
45. Naesens R, et al. Central nervous system invasion by community-acquired methicillin-resistant
Staphylococcus aureus. J Med Microbiol. 58(Pt 9): 1247-51, 2009.
46. Kessler AT, et al. Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus
with linezolid. Infection. 35(4): 271-4, 2007.
47. Lee DH, et al. Successful treatment of methicillin-resistant staphylococcus aureus meningitis with
daptomycin. Clin Infect Dis. 47(4):588-90, 2008.
48. Deveikis A, et al. Antimicribial therapy of experimental group B streptococcal infection in mice.
Antimicrob Agents Chemother. 11: 817, 1977.
50